Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genenta Science SPA GNTA

Healthcare Biotechnology
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including... see more

Recent & Breaking News (NDAQ:GNTA)

Genenta Progresses to Higher Dosing Cohort in Temferon(TM) Phase 1/2a Clinical Trial in Glioblastoma Multiforme

GlobeNewswire May 4, 2022

Genenta ASGCT Clinical Data Highlights Temferon(TM) Biological Effects in Glioblastoma

GlobeNewswire May 2, 2022

Genenta Announces Nomination of Mark A. Sirgo as Chair

GlobeNewswire April 27, 2022

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

GlobeNewswire April 20, 2022

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon(TM) in Unmethylated Glioblastoma Multiforme

GlobeNewswire March 9, 2022

Genenta to Participate at Upcoming Investor Conferences

GlobeNewswire February 24, 2022

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

GlobeNewswire December 17, 2021

Genenta Announces Pricing of Upsized Initial Public Offering

GlobeNewswire December 14, 2021